Literature DB >> 8162724

Respiratory muscle rest using nasal BiPAP ventilation in patients with stable severe COPD.

J P Renston1, A F DiMarco, G S Supinski.   

Abstract

To more systematically evaluate the effect of respiratory muscle rest on indices of ventilatory function, nine outpatients with stable, severe COPD were treated with nasal pressure-support ventilation delivered via a nasal ventilatory support system (BiPAP, Respironics, Inc) for 2 h a day for 5 consecutive days. An additional eight control patients were treated with sham-BiPAP. Maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), maximum voluntary ventilation (MVV), arterial blood gas values, Borg dyspnea score, dyspnea-associated functional impairment scales, and distance walked in 6 min were measured in subjects prior to and following the week-long trial. Nasal BiPAP produced a 66.3 +/- 6 percent reduction in peak integrated diaphragmatic electromyographic (EMG) activity. There were no statistically significant changes in MIP, MEP, MVV, arterial pH, PaCO2, or PaO2 or in objective measures of functional impairment from dyspnea in either group after ventilator or sham treatment. However, nasal BiPAP reduced the Borg category score during resting, spontaneous breathing from 2.0 +/- 0.4 to 0.7 +/- 0.3 (p < 0.01) after 5 days of treatment. In contrast, sham BiPAP-treated patients had no change in their dyspnea score, which was 1.8 +/- 0.4 and 1.3 +/- 0.4 before and after sham treatment, respectively. Nasal BiPAP also increased distance walked in 6 min from 780 +/- 155 to 888 +/- 151 ft (p < 0.01) (23,400 +/- 4,650 to 26,640 +/- 4,530 cm) (p < 0.01), whereas sham-BiPAP had no effect (768 +/- 96 and 762 +/- 106 ft [23,040 +/- 2,880 and 22,860 +/- 3,180 cm]) before and after sham treatment, respectively). In conclusion, these results indicate that nasal pressure-support ventilation, delivered via nasal BiPAP, improves exercise capacity and reduces dyspnea over the short term in selected outpatients with stable severe COPD. Whether such short-term improvement can be sustained merits further study.

Entities:  

Mesh:

Year:  1994        PMID: 8162724     DOI: 10.1378/chest.105.4.1053

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  Domiciliary ventilation in chronic obstructive pulmonary disease: where are we?

Authors:  J A Wedzicha; D J Meecham Jones
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 3.  Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01

Review 4.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

5.  Halo-gravity traction combined with assisted ventilation: an effective pre-operative management for severe adult scoliosis complicated with respiratory dysfunction.

Authors:  Hongda Bao; Peng Yan; Mike Bao; Yong Qiu; Zezhang Zhu; Zhen Liu; Jack C Y Cheng; Bobby K W Ng; Feng Zhu
Journal:  Eur Spine J       Date:  2016-05-27       Impact factor: 3.134

6.  Effects of continuous (CPAP) and bi-level positive airway pressure (BiPAP) on extravascular lung water after extubation of the trachea in patients following coronary artery bypass grafting.

Authors:  R Gust; A Gottschalk; H Schmidt; B W Böttiger; H Böhrer; E Martin
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

7.  Noninvasive positive-pressure ventilation: a utilization review of use in a teaching hospital.

Authors:  T Sinuff; D Cook; J Randall; C Allen
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

8.  Physiological effects and optimisation of nasal assist-control ventilation for patients with chronic obstructive pulmonary disease in respiratory failure.

Authors:  C Girault; V Chevron; J C Richard; I Daudenthun; P Pasquis; J Leroy; G Bonmarchand
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 9.  Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease.

Authors:  Fransien M Struik; Yves Lacasse; Roger Goldstein; Huib M Kerstjens; Peter J Wijkstra
Journal:  Cochrane Database Syst Rev       Date:  2013-06-13

Review 10.  Treatment of respiratory failure in COPD.

Authors:  Stephan Budweiser; Rudolf A Jörres; Michael Pfeifer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.